Clinical Trials in Michigan

Showing 41-60 of 16,154 trials

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

NCT07258836

The purpose of the study is to check how safe and well-tolerated \[18F\]LY4214835 injection is in healthy participants and participants with cancer. The study drug will be administered intravenously (IV) (into a vein). Participation in the study will last approximately 35 days.

NeoplasmsHealthy

Eli Lilly and Company41 participantsStarted Dec 2025

New Haven, Connecticut, United States • Boston, Massachusetts, United States • Charlestown, Massachusetts, United States +3 more locations

RECRUITINGPhase 162 miles

A Study of PHST001 in Advanced Solid Tumors

NCT06840886

This is a multi-center, first-in-human (FIH), open-label, Phase 1a/1b dose escalation and dose expansion study to assess the safety, PK, pharmacodynamics, and antitumor activity of PHST001 monotherapy (Phase 1a) or in combination with chemotherapy (Phase 1b) in adult participants with advanced relapsed and/or refractory solid tumors (including but not limited to CNS tumors in Phase 1a only). In Phase 1b cohort expansions, the study will focus on participants with advanced relapsed and/or refractory ovarian cancer, endometrial cancer, and cholangiocarcinoma. The study's primary objective is to evaluate the safety and tolerability of PHST001 and determine the RP2D (Recommended Phase 2 dose) of PHST001 monotherapy and in combination with chemotherapy as well as assess the anti-tumor activity of PHST001 and chemotherapy in Phase 1b.

Advanced Solid TumorsOvarian CancerEndometrial Cancer+2 more

Pheast Therapeutics272 participantsStarted Mar 2025

Beverly Hills, California, United States • Los Angeles, California, United States • Palo Alto, California, United States +17 more locations

A Study of [18F]LY4214835 in Healthy Volunteers and Participants With Cancer

A Study of PHST001 in Advanced Solid Tumors

Find Trials by Condition in Michigan

A Study of LY3841136 Compared With Placebo in Adult Participants With Obesity or Overweight

Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

Roll-over Study to Allow Continued Access to Ribociclib

WATER IV PCa (AS Sub-study)

Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative Colitis and Obesity or Overweight: Phase 3b Study

Long-term Characterization of GORE® TAG® Conformable Thoracic Stent Graft With ACTIVE CONTROL System Performance

Study of Binimetinib in Combination With Pembrolizumab in Advanced Non-Small Cell Lung Cancer

A Study Evaluating the Efficacy and Safety of Mitapivat in Participants With Non-Transfusion-Dependent Alpha- or Beta-Thalassemia (α- or β-NTDT)

A Study to Learn About the Study Medicine Called Berobenatide (PF-08653944) in People With Overweight or Obesity

A Gaucher Disease Gene Therapy Trial With FLT201

Phase III Study to Assess the Safety and Efficacy of SL1002 for Osteoarthritis Knee Pain

Study to Evaluate Tulisokibart in Adults With Psoriatic Arthritis (MK-7240-015)

Obe-cel in Severe, Refractory Systemic Lupus Erythematosus (SLE) With Active Lupus Nephritis (LN)

A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors

Cryoballoon vs. Rhythmia Guided Ablation for Recurrent AFib

Study of GVV858 as a Single Agent or in Combination With Endocrine Therapy in Patients With HR+/HER2- Breast Cancer and Other Advanced Solid Tumors

Trial of Orca-T Following Reduced Intensity or Nonmyeloablative Conditioning in Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome

A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA-positive mCRPC